Comprehensive Therapeutic and Developmental Report: Siplizumab (DB06371)

Molecular Profile and Physicochemical Properties of Siplizumab (MEDI-507)

Identification and Classification

Siplizumab is an investigational, protein-based, biotech therapeutic agent that functions as a potent and selective immunomodulator.[1] As a biological drug, it is classified as a monoclonal antibody (mAb), a modality that leverages the high specificity of the adaptive immune system to target disease-related molecules.[1]

The compound is formally identified by several key international identifiers:

• Generic Name: Siplizumab [1]
• DrugBank Accession Number: DB06371 [1]
• CAS (Chemical Abstracts Service) Number: 288392-69-8 [1]
• UNII (Unique Ingredient Identifier): KUW1QG1ZM3 [2]

Throughout its extensive development history, Siplizumab has been known by various synonyms and external codes, which reflect its journey through different corporate and academic research programs. The most prominent of these are MEDI-507, associated with its development at MedImmune, and TCD 601, linked to its current development by ITB-Med Biopharmaceuticals.[1] Other historical identifiers include Humanized LO-CD2a and ALLOMUNE.[5] This multiplicity of names points toward a protracted and non-linear development pathway, characteristic of a therapeutic asset that has undergone strategic repositioning. The transition from a large pharmaceutical entity (MedImmune, as MEDI-507) to a more specialized biotechnology company (ITB-Med, as TCD 601) suggests a strategic shift from pursuing broad indications to focusing on niche therapeutic areas where the drug's unique mechanism offers a distinct advantage, a common and often successful strategy in modern drug development.

Structural Characteristics